SCHEMBL19274201

SCHEMBL19274201

CC/C=C(\C)CC/C=C(\C)CCC=C(C)C

nearest known ligand 0.76

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.76
MAPT P10636 2/20 0.67
MEN1 O00255 2/20 0.67
CYP3A4 P08684 2/20 0.67
ALOX15 P16050 2/20 0.67
ALDH1A1 P00352 2/20 0.67
UGT1A1 P22309 1/20 0.67
SQLE Q14534 7/20 0.64
KDM4E B2RXH2 1/20 0.59
FNTA P49354 1/20 0.53
FNTB P49356 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5576405 1.00 KMT2A (0.76) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL27099651 1.00 KMT2A (0.76) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL10014861 0.97 KMT2A (0.71) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL10777183 0.97 KMT2A (0.71) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL2016647 0.97 KMT2A (0.71) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL23802597 0.87 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Squalene SCHEMBL890053 0.87 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL8013144 0.87 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
Squalene SCHEMBL21823197 0.87 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15
SCHEMBL21639794 0.87 KMT2A (1.00) KMT2AMAPTMEN1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400529-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2024-12-05 US disclosed
US-12049455-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia STEALTH BIOTHERAPEUTICS INC. (US) 2024-07-30 US disclosed
US-11802100-B2 Olefins and methods for making the same Amyris, Inc. (US) 2023-10-31 US disclosed
US-20230303506-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA STEALTH BIOTHERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20220154092-A1 OLEFINS AND METHODS FOR MAKING THE SAME EUAGORE, LLC 2022-05-19 US disclosed
US-11193078-B2 Olefins and methods for making the same Amyris, Inc. (US) 2021-12-07 US disclosed
WO-2021243171-A1 METHODS OF SYNTHESIZING FARNESYL DIBENZODIAZEPINONES AMO PHARMA LTD (US) 2021-12-02 WO disclosed
EP-3330252-B1 ISOPRENYL COMPOUNDS AND METHODS THEREOF SIGNUM BIOSCIENCES INC (US) 2020-02-12 EP disclosed
US-20190249101-A1 OLEFINS AND METHODS FOR MAKING THE SAME EUAGORE, LLC 2019-08-15 US disclosed
WO-2017143106-A1 COMPOSITIONS AND METHODS FOR TREATING LIVER CANCER GOLDEN BIOTECHNOLOGY CORPORATION (US) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190249101-A1 OLEFINS AND METHODS FOR MAKING THE SAME HSD17B10, DHCR7, HSD17B12 KMT2A 2965/4885MAPT 3763/4885MEN1 2665/4885
US-11193078-B2 Olefins and methods for making the same HSD17B10, DHCR7, HSD17B12 KMT2A 2965/4885MAPT 3763/4885MEN1 2665/4885
US-20230303506-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885
US-20220154092-A1 OLEFINS AND METHODS FOR MAKING THE SAME HSD17B10, DHCR7, HSD17B12 KMT2A 2865/4885MAPT 3808/4885MEN1 2680/4885
US-11802100-B2 Olefins and methods for making the same HSD17B10, DHCR7, HSD17B12 KMT2A 2865/4885MAPT 3808/4885MEN1 2680/4885
US-20240400529-A1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885
US-12049455-B2 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia FH, COQ8A, TFAM KMT2A 2420/4885MAPT 1057/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.